BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sheehan DV, Nakagome K, Asami Y, Pappadopulos EA, Boucher M. Restoring function in major depressive disorder: A systematic review. J Affect Disord 2017;215:299-313. [PMID: 28364701 DOI: 10.1016/j.jad.2017.02.029] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu X, Zhong S, Li Z, Chen J, Wang Y, Lai S, Miao H, Jia Y. Serum copper and zinc levels correlate with biochemical metabolite ratios in the prefrontal cortex and lentiform nucleus of patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2020;99:109828. [PMID: 31778759 DOI: 10.1016/j.pnpbp.2019.109828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kebede D, Fekadu A, Shibre KT, Medhin G, Hanlon C, Mayston R, Alem A. The 11-year functional outcome of bipolar and major depressive disorders in Butajira, Ethiopia. Neurology, Psychiatry and Brain Research 2019;32:68-76. [DOI: 10.1016/j.npbr.2019.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Nagata T, Fujino Y, Ohtani M, Fujimoto K, Nagata M, Kajiki S, Okawara M, Mori K. Work functioning impairment in the course of pharmacotherapy treatment for depression. Sci Rep 2020;10:15712. [PMID: 32973248 DOI: 10.1038/s41598-020-72677-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ng J, Rosenblat JD, Lui LMW, Teopiz KM, Lee Y, Lipsitz O, Mansur RB, Rodrigues NB, Nasri F, Gill H, Cha DS, Subramaniapillai M, Ho RC, Cao B, McIntyre RS. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. J Affect Disord 2021;293:285-94. [PMID: 34225208 DOI: 10.1016/j.jad.2021.06.032] [Reference Citation Analysis]
5 Gu Z, Wang W, Qian H, Zhou A, Sun H, Zhang Q, Li J. Synthesis and antidepressant effect of novel aralkyl piperazine and piperidine derivatives targeting SSRI/5-HT1A/5-HT7. Bioorganic & Medicinal Chemistry Letters 2019;29:126703. [DOI: 10.1016/j.bmcl.2019.126703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Dunn BD, Widnall E, Reed N, Owens C, Campbell J, Kuyken W. Bringing light into darkness: A multiple baseline mixed methods case series evaluation of Augmented Depression Therapy (ADepT). Behav Res Ther 2019;120:103418. [PMID: 31310929 DOI: 10.1016/j.brat.2019.103418] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
7 Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, Fava M. Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies. Neuropsychiatr Dis Treat 2018;14:103-15. [PMID: 29343962 DOI: 10.2147/NDT.S146840] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
8 Zhou R, Chen J, Zhao G, Wang Z, Peng D, Xia W, Mao R, Xu J, Wang F, Zhang C, Wang Y, Yuan C, Su Y, Huang J, Yang T, Wang C, Cui L, Wang J, Palaniyappan L, Fang Y. Neural biomarker of functional disability in major depressive disorder: A structural neuroimaging study. Prog Neuropsychopharmacol Biol Psychiatry 2021;111:110337. [PMID: 33905754 DOI: 10.1016/j.pnpbp.2021.110337] [Reference Citation Analysis]
9 Soares CN, Zhang M, Boucher M. Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine. CNS Spectr 2019;24:322-32. [PMID: 29140227 DOI: 10.1017/S1092852917000633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Naumann J, Kruza I, Denkel L, Kienle G, Huber R. Effects and feasibility of hyperthermic baths in comparison to exercise as add-on treatment to usual care in depression: a randomised, controlled pilot study. BMC Psychiatry 2020;20:536. [PMID: 33176757 DOI: 10.1186/s12888-020-02941-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Juengst S, Nordvik JE, Junttila IS, Smith J, Kew CL, Laukkala T. Mental health assessment in rehabilitation: a descriptive study through an international internet survey. Int J Rehabil Res 2018;41:368-72. [PMID: 29912785 DOI: 10.1097/MRR.0000000000000300] [Reference Citation Analysis]
12 Cha DS, Luo X, Ahmed J, Becirovic L, Cha RH, Mcintyre RS. Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder. Expert Review of Neurotherapeutics 2018;19:777-83. [DOI: 10.1080/14737175.2019.1653759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ślifirski G, Król M, Kleps J, Ulenberg S, Belka M, Bączek T, Siwek A, Stachowicz K, Szewczyk B, Nowak G, Bojarski A, Kozioł AE, Turło J, Herold F. Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands. Eur J Med Chem 2019;166:144-58. [PMID: 30703658 DOI: 10.1016/j.ejmech.2019.01.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
14 Liao SC, Ma HM, Lin YL, Huang WL. Functioning and quality of life in patients with somatic symptom disorder: The association with comorbid depression. Compr Psychiatry 2019;90:88-94. [PMID: 30818088 DOI: 10.1016/j.comppsych.2019.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Batt MM, Duffy KA, Novick AM, Metcalf CA, Epperson CN. Is Postpartum Depression Different From Depression Occurring Outside of the Perinatal Period? A Review of the Evidence. Focus (Am Psychiatr Publ) 2020;18:106-19. [PMID: 33162848 DOI: 10.1176/appi.focus.20190045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
16 Zhao W, Hu Y, Sun Q, Li S, Gao Z, Lin M, Ding Z, Sun J, Li C. Chronic restraint stress increases social interaction in C57BL/6J mice monitoring through MiceProfiler analysis. Anat Rec (Hoboken) 2020;303:2402-14. [PMID: 32478467 DOI: 10.1002/ar.24470] [Reference Citation Analysis]
17 Kim HY, Lee HJ, Jhon M, Kim JW, Kang HJ, Lee JY, Kim SW, Shin IS, Kim JM. Predictors of Remission in Acute and Continuation Treatment of Depressive Disorders. Clin Psychopharmacol Neurosci 2021;19:490-7. [PMID: 34294617 DOI: 10.9758/cpn.2021.19.3.490] [Reference Citation Analysis]
18 Ishigooka J, Hoshino T, Imai T, Yoshida H, Ono M, Ota M, Moriguchi Y, Fujikawa K, Shintani A, Fernandez JL. Patient and Physician Perspectives of Depressive Symptoms and Expectations for Treatment Outcome: Results from a Web-Based Survey. Neuropsychiatr Dis Treat 2021;17:2915-24. [PMID: 34531658 DOI: 10.2147/NDT.S324968] [Reference Citation Analysis]
19 Lee Y, Rosenblat JD, Lee J, Carmona NE, Subramaniapillai M, Shekotikhina M, Mansur RB, Brietzke E, Lee J, Ho RC, Yim SJ, Mcintyre RS. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review. Journal of Affective Disorders 2018;227:406-15. [DOI: 10.1016/j.jad.2017.11.003] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 17.7] [Reference Citation Analysis]
20 Li C, Wang F, Miao P, Yan L, Liu S, Wang X, Jin Z, Gu Z. miR-138 Increases Depressive-Like Behaviors by Targeting SIRT1 in Hippocampus. Neuropsychiatr Dis Treat 2020;16:949-57. [PMID: 32308399 DOI: 10.2147/NDT.S237558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
21 Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG. Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study. Neuropsychiatr Dis Treat 2019;15:2313-23. [PMID: 31616147 DOI: 10.2147/NDT.S206825] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Liu X, Zhong S, Yan L, Zhao H, Wang Y, Hu Y, Jia Y. Correlations Among mRNA Expression Levels of ATP7A, Serum Ceruloplasmin Levels, and Neuronal Metabolism in Unmedicated Major Depressive Disorder. Int J Neuropsychopharmacol 2020;23:642-52. [PMID: 32427278 DOI: 10.1093/ijnp/pyaa038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Segal ZV, Dimidjian S, Beck A, Boggs JM, Vanderkruik R, Metcalf CA, Gallop R, Felder JN, Levy J. Outcomes of Online Mindfulness-Based Cognitive Therapy for Patients With Residual Depressive Symptoms: A Randomized Clinical Trial. JAMA Psychiatry 2020;77:563-73. [PMID: 31995132 DOI: 10.1001/jamapsychiatry.2019.4693] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 23.0] [Reference Citation Analysis]
24 Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr 2019;24:616-27. [PMID: 30802419 DOI: 10.1017/S1092852919000786] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
25 Huang J, Yu Y, Jiang Y, Chen W, Li Y, Shen Y, Zheng Q, Li H. The efficacy and safety of Anyu Peibo Capsule in the treatment of patients with major depressive disorder in China: study protocol for a randomized placebo-controlled trial. Trials 2021;22:585. [PMID: 34479619 DOI: 10.1186/s13063-021-05550-9] [Reference Citation Analysis]
26 Lee CJ, Lee LT, Tsai HC, Chang WH, Lee IH, Chen KC, Chang HH, Chen PS, Yang YK. Factors related to metabolic parameters in medicated patients with major depressive disorder--a naturalistic study. Psychiatry Res 2018;268:28-33. [PMID: 29986174 DOI: 10.1016/j.psychres.2018.06.061] [Reference Citation Analysis]
27 Liu T, Zhong S, Wang B, Liao X, Lai S, Jia Y. Similar profiles of cognitive domain deficits between medication-naïve patients with bipolar II depression and those with major depressive disorder. Journal of Affective Disorders 2019;243:55-61. [DOI: 10.1016/j.jad.2018.05.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
28 Miyata A, Iwamoto K, Kawano N, Aleksic B, Ando M, Ebe K, Fujita K, Yokoyama M, Akiyama T, Igarashi Y, Ozaki N. Driving performance of stable outpatients with depression undergoing real‐world treatment. Psychiatry Clin Neurosci 2018;72:399-408. [DOI: 10.1111/pcn.12648] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
29 Knapstad M, Sæther SMM, Hensing G, Smith ORF. Prompt Mental Health Care (PMHC): work participation and functional status at 12 months post-treatment. BMC Health Serv Res 2020;20:85. [PMID: 32019521 DOI: 10.1186/s12913-020-4932-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sugawara N, Yasui-Furukori N, Tsuji T, Hayashi S, Ajisawa Y, Ochiai T, Imagawa H, Shimoda K. The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms. Neuropsychiatr Dis Treat 2020;16:3063-70. [PMID: 33335397 DOI: 10.2147/NDT.S274608] [Reference Citation Analysis]
31 Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Curr Med Res Opin 2020;36:875-82. [PMID: 31990207 DOI: 10.1080/03007995.2020.1723072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
32 Tutakhail A, Boulet L, Khabil S, Nazari QA, Hamid H, Coudoré F. Neuropathology of Kynurenine Pathway of Tryptophan Metabolism. Curr Pharmacol Rep 2020;6:8-23. [DOI: 10.1007/s40495-019-00208-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Xin J, Yuan M, Peng Y, Wang J. Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder. Front Psychiatry 2020;11:151. [PMID: 32256400 DOI: 10.3389/fpsyt.2020.00151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Cao B, Xu L, Chen Y, Wang D, Lee Y, Rosenblat JD, Gao X, Zhan S, Sun F, McIntyre RS. Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. CNS Spectr 2021;:1-9. [PMID: 33583460 DOI: 10.1017/S1092852921000171] [Reference Citation Analysis]
35 Benoit JRA, Dursun SM, Greiner R, Cao B, Brown MRG, Lam RW, Greenshaw AJ. Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine : Utiliser l'apprentissage machine pour prédire la rémission chez les patients souffrant de trouble dépressif majeur traités par desvenlafaxine. Can J Psychiatry 2021;:7067437211037141. [PMID: 34379019 DOI: 10.1177/07067437211037141] [Reference Citation Analysis]
36 Dominiak M, Antosik-Wójcińska AZ, Baron M, Mierzejewski P. Screening and treatment of depression - recommendations for Polish health professionals. Prz Menopauzalny 2021;20:1-13. [PMID: 33935614 DOI: 10.5114/pm.2021.104207] [Reference Citation Analysis]
37 Ma HY, Wang XM, Huang XJ, Yang CJ, Sheng DF, Yang JJ, Xu MZ. Psychometric Properties of the Chinese Version of the Clinically Useful Depression Outcome Scale for Patients with Major Depressive Disorder. Neuropsychiatr Dis Treat 2021;17:2387-95. [PMID: 34321881 DOI: 10.2147/NDT.S307662] [Reference Citation Analysis]
38 Salvat-Pujol N, Labad J, Urretavizcaya M, De Arriba-Arnau A, Segalàs C, Real E, Ferrer A, Crespo JM, Jiménez-Murcia S, Soriano-Mas C, Menchón JM, Soria V. Childhood Maltreatment and Its Interaction with Hypothalamic-Pituitary-Adrenal Axis Activity and the Remission Status of Major Depression: Effects on Functionality and Quality of Life. Brain Sci 2021;11:495. [PMID: 33924651 DOI: 10.3390/brainsci11040495] [Reference Citation Analysis]
39 Wang Y, Gu JH, Liu L, Liu Y, Tang WQ, Ji CH, Guan W, Zhao XY, Sun YF, Xu DW, Jiang B. Hippocampal PPARα Plays a Role in the Pharmacological Mechanism of Vortioxetine, a Multimodal-Acting Antidepressant. Front Pharmacol 2021;12:673221. [PMID: 34211395 DOI: 10.3389/fphar.2021.673221] [Reference Citation Analysis]
40 Wassink-vossen S, Collard RM, Wardenaar KJ, Verhaak PF, Rhebergen D, Naarding P, Voshaar RCO. Trajectories and determinants of functional limitations in late-life depression: A 2-year prospective cohort study. Eur psychiatr 2019;62:90-6. [DOI: 10.1016/j.eurpsy.2019.09.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Dunn BD, German RE, Khazanov G, Xu C, Hollon SD, Derubeis RJ. Changes in Positive and Negative Affect During Pharmacological Treatment and Cognitive Therapy for Major Depressive Disorder: A Secondary Analysis of Two Randomized Controlled Trials. Clinical Psychological Science 2020;8:36-51. [DOI: 10.1177/2167702619863427] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 7.5] [Reference Citation Analysis]
42 Wang G, You X, Wang X, Xu X, Bai L, Xie J, Yao Z, Yi Q, Ma J, Wang J, Zhuo J, Hu C. Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety. Neuropsychiatr Dis Treat 2018;14:2087-97. [PMID: 30147321 DOI: 10.2147/NDT.S164673] [Reference Citation Analysis]
43 Rodrigues NB, McIntyre RS, Lipsitz O, Lee Y, Subramaniapillai M, Kratiuk K, Majeed A, Nasri F, Gill H, Mansur RB, Rosenblat JD. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence. Psychiatry Res 2021;300:113860. [PMID: 33836470 DOI: 10.1016/j.psychres.2021.113860] [Reference Citation Analysis]
44 Ślifirski G, Król M, Turło J. 5-HT Receptors and the Development of New Antidepressants. Int J Mol Sci 2021;22:9015. [PMID: 34445721 DOI: 10.3390/ijms22169015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Corponi F, Anmella G, Verdolini N, Pacchiarotti I, Samalin L, Popovic D, Azorin JM, Angst J, Bowden CL, Mosolov S, Young AH, Perugi G, Vieta E, Murru A. Symptom networks in acute depression across bipolar and major depressive disorders: A network analysis on a large, international, observational study. Eur Neuropsychopharmacol 2020;35:49-60. [PMID: 32409261 DOI: 10.1016/j.euroneuro.2020.03.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
46 Vittengl JR, Jha MK, Minhajuddin A, Thase ME, Jarrett RB. Quality of life after response to acute-phase cognitive therapy for recurrent depression. J Affect Disord 2021;278:218-25. [PMID: 32971314 DOI: 10.1016/j.jad.2020.09.059] [Reference Citation Analysis]
47 Kuga A, Otsubo T, Tsuji T, Hayashi S, Imagawa H, Fujikoshi S, Escobar R. Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy. Neuropsychiatr Dis Treat 2019;15:809-17. [PMID: 31040680 DOI: 10.2147/NDT.S195445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Ziobrowski HN, Leung LB, Bossarte RM, Bryant C, Keusch JN, Liu H, Puac-Polanco V, Pigeon WR, Oslin DW, Post EP, Zaslavsky AM, Zubizarreta JR, Kessler RC. Comorbid mental disorders, depression symptom severity, and role impairment among Veterans initiating depression treatment through the Veterans Health Administration. J Affect Disord 2021;290:227-36. [PMID: 34004405 DOI: 10.1016/j.jad.2021.04.033] [Reference Citation Analysis]
49 Kim H, Han KM, Choi KW, Tae WS, Kang W, Kang Y, Kim A, Ham BJ. Volumetric alterations in subregions of the amygdala in adults with major depressive disorder. J Affect Disord 2021;295:108-15. [PMID: 34419778 DOI: 10.1016/j.jad.2021.08.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Ota M, Takeda S, Pu S, Matsumura H, Araki T, Hosoda N, Yamamoto Y, Sakakihara A, Kaneko K. The relationship between cognitive distortion, depressive symptoms, and social adaptation: A survey in Japan. J Affect Disord 2020;265:453-9. [PMID: 32090772 DOI: 10.1016/j.jad.2020.01.094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Anmella G, Gil-badenes J, Pacchiarotti I, Verdolini N, Aedo A, Angst J, Azorin J, Bowden CL, Mosolov S, Samalin L, Popovic D, Young AH, Perugi G, Vieta E, Murru A. “Do depressive and manic symptoms differentially impact on functioning in acute depression? Results from a large, cross-sectional study”. Journal of Affective Disorders 2020;261:30-9. [DOI: 10.1016/j.jad.2019.09.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]